PEntoxifylline in Anaemia Resistant to erythropoieting (PEAR)

• Research type

  Research Study

• Full title

  A Single-Centre randomized placebo controlled, double blinded study of Pentoxifylline in End-Stage Renal Disease Patients with Erythropoeitin resistance

• IRAS ID

  103187

• Contact name

  Magdi Yaqoob

• Sponsor organisation

  Barts Health NHS Trust

• Eudract number

  2011-006168-30

• ISRCTN Number

  n/a

• Clinicaltrials.gov Identifier

  n/a

• Research summary

  Rationale: Unfortunately, a considerable proportion of patients with End Stage Renal Failure (ESRD) exhibit a suboptimal response to our only treatment for anaemia (low Hb) called Erythropoetin Stimulating Agent (ESA or commonly known as "EPO"). In some patients, this has been attributed to elevated levels of inflammatory cytokines. In a small uncontrolled study, Pentoxifylline was a useful adjunct for patients with ESA resistance and suppressed inflammatory cytokines secreted by T-cells. Objectives: ?½ To study the effects Pentoxifylline in ESA resistant ESRD patients on haemodialysis in a randomised controlled double-blind study.

• REC name

  London - City & East Research Ethics Committee

• REC reference

  12/LO/1635

• Date of REC Opinion

  8 Jan 2013

• REC opinion

  Further Information Favourable Opinion